Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases

Puntos clave

• To describe non-ICANS neurologic events in patients with relapsed or refractory multiple myeloma treated with ciltacabtagene autoleucel.
• Analyzed data from two large US databases
• Compared rates of neurologic events post-infusion to prior trials
• Assessed real-world treatment outcomes
• Rates of non-ICANS neurologic events were comparable or lower than previous trials
• Supports the favorable risk-benefit profile of ciltacabtagene autoleucel for routine use